CellaVision AB (publ)

LSE:0MR5 Stock Report

Market Cap: SEK 5.2b

CellaVision Valuation

Is 0MR5 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0MR5 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 0MR5 (SEK215.5) is trading below our estimate of fair value (SEK301.94)

Significantly Below Fair Value: 0MR5 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0MR5?

Key metric: As 0MR5 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 0MR5. This is calculated by dividing 0MR5's market cap by their current earnings.
What is 0MR5's PE Ratio?
PE Ratio34.5x
EarningsSEK 150.21m
Market CapSEK 5.18b

Price to Earnings Ratio vs Peers

How does 0MR5's PE Ratio compare to its peers?

The above table shows the PE ratio for 0MR5 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average31x
NIOX NIOX Group
23.2x17.1%UK£255.5m
EKF EKF Diagnostics Holdings
24.4xn/aUK£116.6m
SN. Smith & Nephew
35.4x22.5%UK£8.6b
AMS Advanced Medical Solutions Group
41x23.0%UK£456.3m
0MR5 CellaVision
34.5x23.4%SEK 5.2b

Price-To-Earnings vs Peers: 0MR5 is expensive based on its Price-To-Earnings Ratio (34.5x) compared to the peer average (31x).

Price to Earnings Ratio vs Industry

How does 0MR5's PE Ratio compare vs other companies in the European Medical Equipment Industry?

3 CompaniesPrice / EarningsEstimated GrowthMarket Cap
0MR5 34.5xIndustry Avg. 29.5xNo. of Companies7PE01632486480+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 0MR5 is expensive based on its Price-To-Earnings Ratio (34.5x) compared to the European Medical Equipment industry average (29.5x).

Price to Earnings Ratio vs Fair Ratio

What is 0MR5's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0MR5 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio34.5x
Fair PE Ratio34.7x

Price-To-Earnings vs Fair Ratio: 0MR5 is good value based on its Price-To-Earnings Ratio (34.5x) compared to the estimated Fair Price-To-Earnings Ratio (34.7x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0MR5 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentSEK 215.50
SEK 270.00
+25.3%
6.9%SEK 300.00SEK 250.00n/a4
Nov ’25SEK 239.75
SEK 262.50
+9.5%
8.7%SEK 300.00SEK 240.00n/a4
Oct ’25SEK 294.75
SEK 260.50
-11.6%
11.1%SEK 310.00SEK 240.00n/a4
Sep ’25SEK 266.00
SEK 256.75
-3.5%
8.7%SEK 295.00SEK 240.00n/a4
Aug ’25SEK 260.50
SEK 255.50
-1.9%
9.2%SEK 295.00SEK 235.00n/a4
Jul ’25SEK 253.00
SEK 256.25
+1.3%
10.0%SEK 300.00SEK 235.00n/a4
Jun ’25SEK 263.00
SEK 257.50
-2.1%
9.6%SEK 300.00SEK 240.00n/a4
May ’25SEK 230.00
SEK 257.50
+12.0%
9.6%SEK 300.00SEK 240.00n/a4
Apr ’25SEK 239.02
SEK 256.25
+7.2%
9.9%SEK 300.00SEK 240.00n/a4
Mar ’25SEK 256.25
SEK 256.25
0%
9.9%SEK 300.00SEK 240.00n/a4
Feb ’25SEK 199.60
SEK 204.25
+2.3%
12.3%SEK 230.00SEK 165.00n/a4
Jan ’25SEK 212.00
SEK 191.75
-9.6%
11.2%SEK 222.00SEK 165.00n/a4
Dec ’24SEK 176.17
SEK 191.75
+8.8%
11.2%SEK 222.00SEK 165.00n/a4
Nov ’24SEK 137.63
SEK 200.50
+45.7%
7.4%SEK 222.00SEK 180.00SEK 239.754
Oct ’24SEK 160.00
SEK 220.00
+37.5%
8.5%SEK 250.00SEK 200.00SEK 294.754
Sep ’24SEK 197.80
SEK 220.00
+11.2%
8.5%SEK 250.00SEK 200.00SEK 266.004
Aug ’24SEK 218.00
SEK 220.00
+0.9%
8.5%SEK 250.00SEK 200.00SEK 260.504
Jul ’24SEK 184.20
SEK 197.50
+7.2%
11.9%SEK 220.00SEK 165.00SEK 253.004
Jun ’24SEK 203.00
SEK 197.50
-2.7%
11.9%SEK 220.00SEK 165.00SEK 263.004
May ’24SEK 175.00
SEK 222.50
+27.1%
20.1%SEK 280.00SEK 160.00SEK 230.004
Apr ’24SEK 184.86
SEK 247.50
+33.9%
11.1%SEK 280.00SEK 205.00SEK 239.024
Mar ’24SEK 201.50
SEK 250.00
+24.1%
9.5%SEK 280.00SEK 215.00SEK 256.254
Feb ’24SEK 248.99
SEK 260.00
+4.4%
4.7%SEK 275.00SEK 245.00SEK 199.603
Jan ’24SEK 232.50
SEK 260.00
+11.8%
4.7%SEK 275.00SEK 245.00SEK 212.003
Dec ’23SEK 226.07
SEK 252.50
+11.7%
3.0%SEK 260.00SEK 245.00SEK 176.172
Nov ’23SEK 209.50
SEK 252.50
+20.5%
3.0%SEK 260.00SEK 245.00SEK 137.632

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

Elevance Health

US$93.4b

Operates as a health benefits company in the United States.

0HG8

US$401.70

7D

-0.06%

1Y

-16.0%

Centene

US$30.5b

Operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States.

0HVB

US$60.47

7D

5.2%

1Y

-18.4%

Patterson Companies

US$1.8b

Engages in the distribution of dental and animal health products in the United States, the United Kingdom, and Canada.

0KGB

US$20.26

7D

3.6%

1Y

-37.4%